annual cash & cash equivalents:
$13.46B-$971.00M(-6.73%)Summary
- As of today (August 23, 2025), NVS annual cash & cash equivalents is $13.46 billion, with the most recent change of -$971.00 million (-6.73%) on December 31, 2024.
- During the last 3 years, NVS annual cash & cash equivalents has fallen by -$14.87 billion (-52.50%).
- NVS annual cash & cash equivalents is now -52.50% below its all-time high of $28.33 billion, reached on December 31, 2021.
Performance
NVS Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$7.00B-$196.01M(-2.72%)Summary
- As of today (August 23, 2025), NVS quarterly cash & cash equivalents is $7.00 billion, with the most recent change of -$196.01 million (-2.72%) on June 30, 2025.
- Over the past year, NVS quarterly cash & cash equivalents has dropped by -$1.44 billion (-17.01%).
- NVS quarterly cash & cash equivalents is now -75.29% below its all-time high of $28.33 billion, reached on December 31, 2021.
Performance
NVS quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NVS Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.7% | -17.0% |
| 3 y3 years | -52.5% | -64.6% |
| 5 y5 years | +17.6% | +11.2% |
NVS Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -52.5% | at low | -64.6% | at low |
| 5 y | 5-year | -52.5% | +17.6% | -75.3% | +71.7% |
| alltime | all time | -52.5% | +165.2% | -75.3% | +165.3% |
NVS Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $7.00B(-2.7%) |
| Mar 2025 | - | $7.20B(-46.5%) |
| Dec 2024 | $13.46B(-6.7%) | $13.46B(-4.0%) |
| Sep 2024 | - | $14.02B(+66.2%) |
| Jun 2024 | - | $8.44B(-13.5%) |
| Mar 2024 | - | $9.75B(-32.4%) |
| Dec 2023 | $14.43B(-23.8%) | $14.43B(+13.7%) |
| Sep 2023 | - | $12.70B(+13.6%) |
| Jun 2023 | - | $11.17B(-8.9%) |
| Mar 2023 | - | $12.26B(-35.2%) |
| Dec 2022 | $18.93B(-33.2%) | $18.93B(-0.9%) |
| Sep 2022 | - | $19.10B(-3.3%) |
| Jun 2022 | - | $19.76B(+5.0%) |
| Mar 2022 | - | $18.81B(-33.6%) |
| Dec 2021 | $28.33B(+145.0%) | $28.33B(+247.1%) |
| Sep 2021 | - | $8.16B(+52.4%) |
| Jun 2021 | - | $5.36B(+31.4%) |
| Mar 2021 | - | $4.08B(-64.7%) |
| Dec 2020 | $11.56B(+1.0%) | $11.56B(+6.4%) |
| Sep 2020 | - | $10.87B(+72.7%) |
| Jun 2020 | - | $6.29B(+26.5%) |
| Mar 2020 | - | $4.97B(-56.6%) |
| Dec 2019 | $11.45B(-28.2%) | $11.45B(+31.3%) |
| Sep 2019 | - | $8.72B(-15.7%) |
| Jun 2019 | - | $10.34B(+45.3%) |
| Mar 2019 | - | $7.11B(-55.4%) |
| Dec 2018 | $15.95B(+68.2%) | $15.95B(+8.4%) |
| Sep 2018 | - | $14.71B(+11.9%) |
| Jun 2018 | - | $13.15B(+104.7%) |
| Mar 2018 | - | $6.42B(-32.3%) |
| Dec 2017 | $9.48B(+22.0%) | $9.48B(+0.7%) |
| Sep 2017 | - | $9.42B(+11.7%) |
| Jun 2017 | - | $8.44B(+2.4%) |
| Mar 2017 | - | $8.24B(+5.9%) |
| Dec 2016 | $7.78B(+42.8%) | $7.78B(-0.1%) |
| Sep 2016 | - | $7.79B(+35.6%) |
| Jun 2016 | - | $5.74B(+12.9%) |
| Mar 2016 | - | $5.09B(-6.6%) |
| Dec 2015 | $5.45B(-60.7%) | $5.45B(-10.2%) |
| Sep 2015 | - | $6.06B(+3.2%) |
| Jun 2015 | - | $5.88B(-20.2%) |
| Mar 2015 | - | $7.36B(-46.9%) |
| Dec 2014 | $13.86B(+50.3%) | $13.86B(+32.9%) |
| Sep 2014 | - | $10.43B(+42.2%) |
| Jun 2014 | - | $7.33B(-5.0%) |
| Mar 2014 | - | $7.72B(-16.3%) |
| Dec 2013 | $9.22B | $9.22B(+25.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $7.34B(+39.8%) |
| Jun 2013 | - | $5.25B(-13.0%) |
| Mar 2013 | - | $6.04B(-25.7%) |
| Dec 2012 | $8.12B(+60.0%) | $8.12B(+40.0%) |
| Sep 2012 | - | $5.80B(-5.0%) |
| Jun 2012 | - | $6.11B(+13.3%) |
| Mar 2012 | - | $5.39B(+6.2%) |
| Dec 2011 | $5.08B(-37.7%) | $5.08B(-8.9%) |
| Sep 2011 | - | $5.57B(-0.6%) |
| Jun 2011 | - | $5.60B(-36.1%) |
| Mar 2011 | - | $8.76B(+7.5%) |
| Dec 2010 | $8.15B(-53.3%) | $8.15B(+2.0%) |
| Sep 2010 | - | $7.99B(-65.2%) |
| Jun 2010 | - | $23.00B(+15.6%) |
| Mar 2010 | - | $19.90B(+14.0%) |
| Dec 2009 | $17.45B(+185.3%) | $17.45B(+23.4%) |
| Sep 2009 | - | $14.14B(+20.6%) |
| Jun 2009 | - | $11.73B(+48.4%) |
| Mar 2009 | - | $7.91B(+29.2%) |
| Dec 2008 | $6.12B(-53.7%) | $6.12B(-23.0%) |
| Sep 2008 | - | $7.95B(-50.9%) |
| Jun 2008 | - | $16.19B(+21.2%) |
| Mar 2008 | - | $13.36B(+1.2%) |
| Dec 2007 | $13.20B(+65.9%) | $13.20B(-9.2%) |
| Sep 2007 | - | $14.53B(+91.8%) |
| Jun 2007 | - | $7.58B(+9.6%) |
| Mar 2007 | - | $6.91B(-13.1%) |
| Dec 2006 | $7.96B(-27.2%) | $7.96B(-6.4%) |
| Sep 2006 | - | $8.50B(+15.6%) |
| Jun 2006 | - | $7.36B(-33.5%) |
| Mar 2006 | - | $11.06B(+1.2%) |
| Dec 2005 | $10.93B(-21.5%) | $10.93B(+36.9%) |
| Sep 2005 | - | $7.98B(-15.4%) |
| Jun 2005 | - | $9.43B(-23.4%) |
| Mar 2005 | - | $12.32B(-11.5%) |
| Dec 2004 | $13.93B(+4.8%) | $13.93B(+21.1%) |
| Sep 2004 | - | $11.50B(-13.5%) |
| Dec 2003 | $13.29B(+8.6%) | $13.29B(+8.6%) |
| Dec 2002 | $12.24B(-3.3%) | $12.24B(+18.2%) |
| Sep 2002 | - | $10.36B(-19.3%) |
| Jun 2002 | - | $12.84B(-2.4%) |
| Dec 2001 | - | $13.16B(+398.7%) |
| Jun 2001 | - | $2.64B(-51.6%) |
| Dec 2000 | $12.66B(+24.2%) | $5.45B(+59.5%) |
| Jun 2000 | - | $3.42B |
| Dec 1999 | $10.20B(-23.7%) | - |
| Dec 1995 | $13.36B | - |
FAQ
- What is Novartis AG annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Novartis AG?
- What is Novartis AG annual cash & cash equivalents year-on-year change?
- What is Novartis AG quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Novartis AG?
- What is Novartis AG quarterly cash & cash equivalents year-on-year change?
What is Novartis AG annual cash & cash equivalents?
The current annual cash & cash equivalents of NVS is $13.46B
What is the all time high annual cash & cash equivalents for Novartis AG?
Novartis AG all-time high annual cash & cash equivalents is $28.33B
What is Novartis AG annual cash & cash equivalents year-on-year change?
Over the past year, NVS annual cash & cash equivalents has changed by -$971.00M (-6.73%)
What is Novartis AG quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of NVS is $7.00B
What is the all time high quarterly cash & cash equivalents for Novartis AG?
Novartis AG all-time high quarterly cash & cash equivalents is $28.33B
What is Novartis AG quarterly cash & cash equivalents year-on-year change?
Over the past year, NVS quarterly cash & cash equivalents has changed by -$1.44B (-17.01%)